This portion of our website contains archival information. Archived information should be considered accurate only as of the date listed next to the event. Archived information may be superseded by more recent information we have disclosed in later presentations, press releases, filings with the Securities and Exchange Commission or otherwise. Archived information may contain forward-looking statements. Actual results may materially differ based on several factors, including those described in the archived information, press releases and our filings with the SEC.
Current | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999
- August 05, 2008
Targacept Reports Second Quarter 2008 Financial Results - July 29, 2008
Targacept to Report Second Quarter 2008 Financial Results on August 5, 2008 - July 21, 2008
Targacept Initiates Phase 2b Clinical Trial of TC-5214 as Augmentation Treatment in Major Depressive Disorder - June 25, 2008
Targacept Set to Join Russell 3000 Index - June 10, 2008
Targacept and AstraZeneca Initiate Clinical Trial of AZD3480 in Adult ADHD - June 05, 2008
Targacept to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference - May 06, 2008
Targacept Reports First Quarter 2008 Financial Results - May 05, 2008
Targacept Announces Designation of Lead Compound in Smoking Cessation Program - April 30, 2008
Targacept to Present at Deutsche Bank 33rd Annual Health Care Conference - April 29, 2008
Targacept to Report First Quarter 2008 Financial Results on May 6, 2008 - March 17, 2008
Targacept Initiates Clinical Development of TC-5214 as Augmentation Therapy for Major Depressive Disorder - March 11, 2008
Targacept to Present at Cowen and Company 28th Annual Health Care Conference - February 12, 2008
Targacept Reports Fourth Quarter and 2007 Financial Results - February 06, 2008
Targacept to Present at BIO CEO & Investor Conference - February 05, 2008
Targacept to Report Fourth Quarter and 2007 Financial Results on February 12, 2008 - January 24, 2008
Targacept Announces Exercise of Underwriters’ Overallotment Option and Closing of $30.9 Million Public Offering - January 17, 2008
Targacept Announces the Pricing of a Public Offering of 3.8 Million Shares of its Common Stock